Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-05-27 4:34 pm Sale |
2022-05-25 | 13D | Genocea Biosciences, Inc. GNCA |
New Enterprise Associates 16, L.P. | 0 0.000% |
-15,414,495 (Position Closed) |
Filing History |
| 2022-02-14 4:09 pm Purchase |
2021-12-31 | 13G | Genocea Biosciences, Inc. GNCA |
Commodore Capital LP | 3,079,756 5.400% |
208,132 (+7.25%) |
Filing History |
| 2022-02-14 06:19 am Sale |
2021-12-31 | 13G | Genocea Biosciences, Inc. GNCA |
Citadel Advisors LLC | 3,535,358 6.200% |
-51,718 (-1.44%) |
Filing History |
| 2022-02-11 7:54 pm Purchase |
2021-12-31 | 13G | Genocea Biosciences, Inc. GNCA |
BIOTECHNOLOGY VALUE FUND L P | 5,930,353 9.990% |
644,804 (+12.20%) |
Filing History |
| 2022-02-10 4:55 pm Purchase |
2021-12-31 | 13G | Genocea Biosciences, Inc. GNCA |
GLAXOSMITHKLINE PLC | 5,861,389 9.900% |
644,000 (+12.34%) |
Filing History |
| 2021-04-13 7:08 pm Sale |
2020-07-24 | 13D | Genocea Biosciences, Inc. GNCA |
New Enterprise Associates 16, L.P. | 15,414,495 26.300% |
-1,558,333 (-9.18%) |
Filing History |
| 2021-03-31 07:14 am Purchase |
2021-03-22 | 13G | Genocea Biosciences, Inc. GNCA |
Commodore Capital LP | 2,871,624 5.400% |
2,871,624 (New Position) |
Filing History |
| 2021-02-16 4:30 pm Purchase |
2020-12-31 | 13G | Genocea Biosciences, Inc. GNCA |
Citadel Advisors LLC | 3,587,076 6.700% |
154,690 (+4.51%) |
Filing History |
| 2021-02-16 09:57 am Sale |
2020-12-31 | 13G | Genocea Biosciences, Inc. GNCA |
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 1,769,170 3.300% |
-290 (-0.02%) |
Filing History |
| 2021-02-12 5:12 pm Purchase |
2020-12-31 | 13G | Genocea Biosciences, Inc. GNCA |
GLAXOSMITHKLINE PLC | 5,217,389 9.900% |
1,540,622 (+41.90%) |
Filing History |
| 2021-02-12 5:03 pm Purchase |
2020-12-31 | 13G | Genocea Biosciences, Inc. GNCA |
BIOTECHNOLOGY VALUE FUND L P | 5,285,549 9.990% |
2,123,881 (+67.18%) |
Filing History |
| 2021-02-12 4:30 pm Sale |
2020-12-31 | 13G | Genocea Biosciences, Inc. GNCA |
Vivo Opportunity LLC | 613,437 1.200% |
-830,401 (-57.51%) |
Filing History |
| 2021-02-12 08:04 am Purchase |
2020-12-31 | 13G | Genocea Biosciences, Inc. GNCA |
AVORO CAPITAL ADVISORS LLC | 33,613,444 9.990% |
33,613,444 (New Position) |
Filing History |
| 2020-08-03 2:22 pm Purchase |
2020-07-24 | 13D | Genocea Biosciences, Inc. GNCA |
New Enterprise Associates 16, L.P. | 16,972,828 48.700% |
8,004,211 (+89.25%) |
Filing History |
| 2020-07-31 4:31 pm Purchase |
2020-07-22 | 13G | Genocea Biosciences, Inc. GNCA |
Citadel Advisors LLC | 3,432,386 6.500% |
3,432,386 (New Position) |
Filing History |